Potential use of β3-adrenoceptor antagonists in heart failure therapy

Cardiovascular Drug Reviews

Volumn 20, Issue 1, 2002, Pages 19-26

  Moniotte, Stéphane ^a   Balligand, Jean Luc ^a  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

Author keywords

Cardiac contractility; Catecholamines; Heart failure; 3 adrenoceptors

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT;

DISEASE ASSOCIATION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; HUMAN; INOTROPISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; TREATMENT PLANNING;

EID: 0036073114     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2002.tb00079.x     Document Type: Review

References (58)

1. Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences
2. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system
3. 3-adrenergic activation of adenylyl cyclase in mouse white adipocytes: Modulation by GTP and effect of obesity
4. Radioimmunochemical quantification of Gi alpha in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure
5. The adrenergic nervous system in heart failure
6. Changes in myocardial and vascular receptors in heart failure
7. 1-receptor down-regulation in heart failure
8. Beta-adrenergic function in heart muscle disease and heart failure
9. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms
10. 2-adrenoceptors in both atria and ventricles in severe congestive cardio myopathy
11. Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols
12. 3-adrenergic receptor antagonists
13. 3-adrenergic receptor
14. 2-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-dependent coupling to phosphatidylinositol 3′-kinase
15. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
16. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway
17. 2-adrenergic receptors on cardiac myocyte apoptosis: Role of a pertussis toxin-sensitive G protein
18. Transgenic Galphaq overexpression induces cardiac contractile failure in mice
19. 3-selective adrenoceptor antagonist, SR 59230A
20. 3-adrenergic receptor
21. 1-adrenergic receptor transgenic mice
22. Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart
23. Rationale for beta-adrenergic blocking drugs in cardiomyopathy
24. Importance of adrenergic nervous system in the support of circulatory function in patients with congestive heart failure
25. 3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle
26. 3-adrenoceptor in the human heart
27. Norepinephrine infusions in congestive heart failure
28. Nitric oxide inhibits creatine kinase and regulates rat heart contractile reserve
29. Why do patients with congestive heart failure tolerate the initiation of beta-blocker therapy?
30. Norepinephrine spillover to plasma in patients with congestive heart failure: Evidence of increased overall and cardiorenal sympathetic nervous activity
31. Adverse effects of chronic endogenous sympathetic drive induced by cardiac GS alpha overexpression
32. 3-adrenoreceptors to the KvLQT1/MinK potassium channel
33. 3-adrenoceptor in the rat
34. Adverse consequences of high sympathetic nervous activity in the failing human heart
35. Nitric oxide and cardiac function
36. 3-adrenoceptor expression in white fat cells
37. 3, adrenoceptor control the cystic fibrosis transmembrane conductance regulator through a cAMP/protein kinase A-independent pathway
38. 3 adrenoceptors regulate CFTR conductance through a PTX-sensitive G protein
39. 2 adrenergic receptor overexpression in mouse hearts
40. 3-adrenoceptors in the pithed rat
41. 3-selective antagonists, aryloxypropanolaminotetralins
42. Adrenergic effects on the biology of the adult mammalian cardiocyte
43. 2- current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes
44. 2- current. Involvement of cGMP- inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation
45. IB-adrenergic receptor in transgenic mice induces cardiac hypertrophy
46. 3-adrenoceptor and its coupled Gi-protein
47. 3-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium
48. 3-adrenergic receptor antagonist SR 59230A in rat brown adipocytes
49. Pathophysiology of chronic heart failure
50. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA
51. Novel cardiac myofilament desensitizing factor released by endocardial and vascular endothelial cells
52. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure
53. β-adrenergic receptor desensitisation may serve a cardioprotective role
54. Plasma norepinephrine in congestive heart failure
55. Inhibition of cytochrome c oxidase in turnover by nitric oxide: Mechanism and implications for control of respiration
56. 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta
57. 1-adrenergic receptors in the failing human heart
58. Nitric oxide donor SIN-1 inhibits mammalian cardiac calcium current through cGMP-dependent protein kinase